Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04970901 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
A Phase 1 study of B-Cell Non-Hodgkin Lymphoma and Refractory B-Cell Non-Hodgkin Lymphoma, sponsored by ADC Therapeutics S.A..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT04970901: Recruiting Phase 1 study of B-Cell Non-Hodgkin Lymphoma and Refractory B-Cell Non-Hodgkin Lymphoma, sponsored by ADC Therapeutics S.A..
NCT04970901 is a Phase 1 study of B-Cell Non-Hodgkin Lymphoma and Refractory B-Cell Non-Hodgkin Lymphoma that is actively recruiting participants, run by ADC Therapeutics S.A.. The registered enrollment target is 200 participants, above the 121-participant average among 24 other B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (65% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04970901, a Phase 1 study of B-Cell Non-Hodgkin Lymphoma and Refractory B-Cell Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by ADC Therapeutics S.A..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Mosunetuzumab
- DRUG Glofitamab
- DRUG Loncastuximab Tesirine
- DRUG Polatuzumab Vedotin
Study Locations (20)
Florida
- Sylvester Comprehensive Cancer Center - Miami
- Miami Cancer Institute - Miami
- Memorial Cancer Institute - Memorial Hospital West - Pembroke Pines
California
- University of California San Francisco - Fresno Center for Medical Education and Research - Clovis
- Scripps Health - Prebys Cancer Center - San Diego
Georgia
- Winship Cancer Institute of Emory University - Atlanta
- The Blood and Marrow Transplant Group of Georgia - Atlanta
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Pennsylvania
- Penn Medicine - Perelman Center for Advanced Medicine - Philadelphia
- Allegheny Health Network - West Penn Hospital - Pittsburgh
Iowa
- Mission Cancer + Blood - Mission Cancer Foundation - Des Moines
Minnesota
- University of Minnesota - Minneapolis
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-06-17 |
| Est. Completion | 2027-10-29 |
| Phase | Phase 1 |
What NCT04970901 shows while recruiting
NCT04970901 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 121-participant average among 24 other B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (65% higher).
The record links to 3 conditions, with B-Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Obinutuzumab is the first listed.
NCT04970901 names 20 study sites across 14 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT04970901 about?
NCT04970901 is a clinical study titled "A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)". The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.
What is the current status of trial NCT04970901?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2022-06-17. Estimated completion is 2027-10-29.
What conditions does trial NCT04970901 study?
This clinical trial studies the following conditions: B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT04970901?
The interventions under investigation include: Obinutuzumab (DRUG), Mosunetuzumab (DRUG), Glofitamab (DRUG), Loncastuximab Tesirine (DRUG), Polatuzumab Vedotin (DRUG).
Who is sponsoring clinical trial NCT04970901?
This trial is sponsored by ADC Therapeutics S.A., which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04970901 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-Cell Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04970901's enrollment target sits among peer trials
200 6th of 24 higher than 19 of 24 other B-Cell Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other B-Cell Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RECRUITING · Phase 1
-
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
RECRUITING · Phase 1
-
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI